KR102488479B1 - 인플루엔자 바이러스 감염에 사용하기 위한 인돌 - Google Patents

인플루엔자 바이러스 감염에 사용하기 위한 인돌 Download PDF

Info

Publication number
KR102488479B1
KR102488479B1 KR1020177005979A KR20177005979A KR102488479B1 KR 102488479 B1 KR102488479 B1 KR 102488479B1 KR 1020177005979 A KR1020177005979 A KR 1020177005979A KR 20177005979 A KR20177005979 A KR 20177005979A KR 102488479 B1 KR102488479 B1 KR 102488479B1
Authority
KR
South Korea
Prior art keywords
mmol
amino
added
methyl
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177005979A
Other languages
English (en)
Korean (ko)
Other versions
KR20170039275A (ko
Inventor
팀 휴고 마리아 욘커스
피에르 쟝-마리 베르나르 라보이송
제롬 에밀 조르쥬 길레몽
고완 데이비드 크레이그 맥
베르너 콘스탄트 요한 엠브레흐츠
루드빅 파울 쿠이만스
앙트완느 벤자민 미체우트
Original Assignee
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 filed Critical 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니
Publication of KR20170039275A publication Critical patent/KR20170039275A/ko
Application granted granted Critical
Publication of KR102488479B1 publication Critical patent/KR102488479B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020177005979A 2014-08-08 2015-08-07 인플루엔자 바이러스 감염에 사용하기 위한 인돌 Active KR102488479B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14180331 2014-08-08
EPEP14180331.2 2014-08-08
PCT/EP2015/068257 WO2016020526A1 (en) 2014-08-08 2015-08-07 Indoles for use in influenza virus infection

Publications (2)

Publication Number Publication Date
KR20170039275A KR20170039275A (ko) 2017-04-10
KR102488479B1 true KR102488479B1 (ko) 2023-01-12

Family

ID=51298610

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177005979A Active KR102488479B1 (ko) 2014-08-08 2015-08-07 인플루엔자 바이러스 감염에 사용하기 위한 인돌

Country Status (18)

Country Link
US (1) US10597390B2 (https=)
EP (1) EP3177609A1 (https=)
JP (1) JP6577570B2 (https=)
KR (1) KR102488479B1 (https=)
CN (1) CN106573920B (https=)
AU (1) AU2015298876B2 (https=)
BR (1) BR112017002370B1 (https=)
CA (1) CA2954751C (https=)
CL (1) CL2017000309A1 (https=)
EA (1) EA201790266A1 (https=)
IL (1) IL250408B (https=)
MA (1) MA40547A (https=)
MX (1) MX381488B (https=)
PH (1) PH12017500207A1 (https=)
SG (1) SG11201700956VA (https=)
UA (1) UA124609C2 (https=)
WO (1) WO2016020526A1 (https=)
ZA (1) ZA201700952B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3141252T (lt) 2009-06-17 2018-11-12 Vertex Pharmaceuticals Inc. Gripo virusų replikacijos inhibitoriai
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
CN106573920B (zh) 2014-08-08 2020-11-10 爱尔兰詹森科学公司 用于在流感病毒感染中使用的吲哚
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
EP3294735B8 (en) 2015-05-13 2022-01-05 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
SG11201804225PA (en) 2015-12-09 2018-06-28 Sunshine Lake Pharma Co Ltd Inhibitors of influenza virus replication, application methods and uses thereof
DK3400225T3 (da) * 2016-01-07 2022-01-03 Janssen Sciences Ireland Unlimited Co Pentansyrederivater substitueret med pyrrolo-[2,3-b]pyrimidinpyridiner til behandling af influenzavirusinfektioner
WO2017133670A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2018033082A1 (en) * 2016-08-16 2018-02-22 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
WO2018041091A1 (en) * 2016-08-30 2018-03-08 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
RU2727772C1 (ru) 2016-09-05 2020-07-23 Гуандун Рэйновент Байотек Ко., Лтд. Производные пиримидина против вируса гриппа
JP7034162B2 (ja) 2016-12-15 2022-03-11 サンシャイン・レイク・ファーマ・カンパニー・リミテッド インフルエンザウイルス複製の阻害剤及びその使用
CA3047404A1 (en) * 2016-12-23 2018-06-28 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use
CN108276401B (zh) 2017-01-05 2020-12-22 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
WO2018157830A1 (en) 2017-03-02 2018-09-07 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
CN108727369B (zh) * 2017-04-25 2023-06-09 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
JP7031002B2 (ja) 2018-03-05 2022-03-07 広東衆生睿創生物科技有限公司 ピリジノイミダゾール系化合物の結晶型、塩型及びその製造方法
WO2021012864A1 (zh) * 2019-07-22 2021-01-28 广东众生睿创生物科技有限公司 嘧啶衍生物的优势盐型及其晶型
CN113045475A (zh) * 2019-12-27 2021-06-29 上海泓博智源医药股份有限公司 一种5-溴-7-甲基吲哚的制备方法
AU2021313150A1 (en) * 2020-07-20 2023-03-16 Nido Biosciences, Inc. Indole compounds as androgen receptor modulators
EP4214201A4 (en) * 2020-09-18 2024-10-09 Sunshine Lake Pharma Co., Ltd. PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRIMIDINE PIPERAZINE COMPOUNDS
CR20250176A (es) * 2022-10-12 2025-06-25 Maze Therapeutics Inc Inhibidores del miembro 19 de la familia de portadores de solutos 6a (slc6a19) y métodos de uso de los mismos

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012032065A1 (en) 2010-09-08 2012-03-15 Glaxo Group Limited Indazole derivatives for use in the treatment of influenza virus infection
WO2012083122A1 (en) 2010-12-16 2012-06-21 Vertex Pharmaceutical Incorporated Inhibitors of influenza viruses replication
WO2013019828A1 (en) 2011-08-01 2013-02-07 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2364340T3 (es) 2004-03-30 2011-08-31 Vertex Pharmaceuticals Incorporated Azaindoles útiles como inhibidores de jak y otras proteína quinasas.
UA95940C2 (uk) 2006-01-17 2011-09-26 Вертекс Фармасьютикалс Інкорпорейтед Азаіндоли як інгібітори кіназ януса
LT3141252T (lt) * 2009-06-17 2018-11-12 Vertex Pharmaceuticals Inc. Gripo virusų replikacijos inhibitoriai
RU2013132681A (ru) * 2010-12-16 2015-01-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы репликации вирусов гриппа
JP6096778B2 (ja) 2011-09-01 2017-03-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ピロロピラジンキナーゼ阻害剤
EP2858984A1 (en) 2012-06-08 2015-04-15 Vertex Pharmaceuticals Inc. Inhibitors of influenza viruses replication
LT3068776T (lt) 2013-11-13 2019-08-12 Vertex Pharmaceuticals Incorporated Gripo virusų replikacijos inhibitoriai
AR101448A1 (es) 2014-08-08 2016-12-21 Bayer Cropscience Ag Compuestos sustituidos por halógeno
CN106573920B (zh) 2014-08-08 2020-11-10 爱尔兰詹森科学公司 用于在流感病毒感染中使用的吲哚
AR101401A1 (es) 2014-08-08 2016-12-14 Bayer Cropscience Ag Derivados de bipirazol, sustituidos con halógeno
CN104592038A (zh) 2015-01-12 2015-05-06 烟台万润精细化工股份有限公司 一种5,5-二甲基-1,3-环己二胺的制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012032065A1 (en) 2010-09-08 2012-03-15 Glaxo Group Limited Indazole derivatives for use in the treatment of influenza virus infection
WO2012083122A1 (en) 2010-12-16 2012-06-21 Vertex Pharmaceutical Incorporated Inhibitors of influenza viruses replication
WO2013019828A1 (en) 2011-08-01 2013-02-07 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication

Also Published As

Publication number Publication date
US10597390B2 (en) 2020-03-24
ZA201700952B (en) 2018-12-19
IL250408A0 (en) 2017-03-30
KR20170039275A (ko) 2017-04-10
JP2017523225A (ja) 2017-08-17
MX381488B (es) 2025-03-12
CA2954751C (en) 2023-01-17
SG11201700956VA (en) 2017-03-30
CA2954751A1 (en) 2016-02-11
AU2015298876B2 (en) 2020-02-13
EP3177609A1 (en) 2017-06-14
WO2016020526A1 (en) 2016-02-11
AU2015298876A1 (en) 2017-02-02
BR112017002370A2 (pt) 2017-12-05
MX2017001752A (es) 2018-02-08
US20170226102A1 (en) 2017-08-10
BR112017002370B1 (pt) 2022-11-22
EA201790266A1 (ru) 2017-06-30
CN106573920A (zh) 2017-04-19
PH12017500207B1 (en) 2017-07-10
JP6577570B2 (ja) 2019-09-18
CN106573920B (zh) 2020-11-10
CL2017000309A1 (es) 2017-08-18
PH12017500207A1 (en) 2017-07-10
MA40547A (fr) 2017-06-14
UA124609C2 (uk) 2021-10-20
IL250408B (en) 2020-08-31

Similar Documents

Publication Publication Date Title
KR102488479B1 (ko) 인플루엔자 바이러스 감염에 사용하기 위한 인돌
KR102531340B1 (ko) 인플루엔자 바이러스 감염에 사용하기 위한 피롤로피리미딘
US11117887B2 (en) Aryl substituted pyrimidines for use in influenza virus infection
ES2882671T3 (es) Indoles heterocíclicos para su uso en infecciones por el virus de la gripe
JP7001601B2 (ja) インフルエンザウイルス感染に使用するための官能化ペンタン酸
US11491157B2 (en) Cycloalkyl substituted pyrazolopyrimidines having activity against RSV
HK1236532B (zh) 用於在流感病毒感染中使用的吲哚
HK1236532A1 (en) Indoles for use in influenza virus infection

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170302

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200717

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220706

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20221007

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230110

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230110

End annual number: 3

Start annual number: 1

PG1601 Publication of registration